San Francisco, CA. Acteris Inc. today announced the signing of an option to license a novel therapeutic and diagnostic platform discovered in the laboratories of Paul Tumeh MD and Antoni Ribas MD, PhD at UCLA. The Company will develop this platform for novel cancer immunotherapies as well as diagnostics assessing the efficacy of immunotherapies for the treatment of solid tumors. Coincident with this license, the UCLA team published this foundational publication in the journal Nature.
“We are delighted to have the opportunity to build on such an impressive set of discoveries by two pioneers in the field of cancer immunotherapy,” said Daniel Dornbusch, CEO of Acteris. “These new insights into the activity of checkpoint inhibitors, response in specific types of tumors, validated prediction of therapeutic response, as well as identification of several phenotypes defined by the tumor microenvironment demonstrate the groundbreaking nature of their work.” He added, “We believe these will position Acteris well to develop the next generations of cancer immunotherapies. We will be seeking a variety of collaborations within the industry to enable these discoveries to best help patients, their physicians, and their families.”
About Acteris, Inc.
Acteris, Inc. is a privately held development stage biotechnology company engaged in improving development and use of novel cancer immunotherapeutic products. It focuses on targeting cancer immunotherapeutic products to specific tumors, patients, and therapeutic combinations to maximize patient outcomes. Acteris is based in San Francisco, CA. For more information, visit the company’s website at www.acterisinc.com.
Daniel Dornbusch, (888) 774-7472